BeyondSpring (BYSI) Total Non-Current Liabilities (2019 - 2026)
BeyondSpring's (BYSI) quarterly Total Non-Current Liabilities came in at $36.4 million in Q2 2026, down 1.14% year-over-year from $36.9 million in Q2 2025, and little changed quarter-over-quarter from $36.4 million in Q1 2026.
Analysis
BeyondSpring (BYSI) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
BeyondSpring has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $36.4 million for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities fell 1.14% year-over-year to $36.4 million; the TTM figure through Jun 2026 stood at $36.4 million (down 1.14% YoY), while the FY2025 annual figure was $36.3 million, down 3.31% from the prior year.
- Total Non-Current Liabilities came in at $36.4 million for Q2 2026 at BeyondSpring, roughly flat from $36.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $41.9 million in Q4 2022 to a low of $36.3 million in Q4 2025.
- Average Total Non-Current Liabilities over 5 years is $38.3 million, with a median of $37.3 million recorded in 2024.
- Year-over-year, Total Non-Current Liabilities surged 400.99% in 2022 and declined 6.75% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $41.9 million in 2022, then fell by 3.74% to $40.3 million in 2023, then decreased by 6.75% to $37.6 million in 2024, then slipped by 3.31% to $36.3 million in 2025, then increased by 0.25% to $36.4 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $36.4 million in Q2 2026, $36.4 million in Q1 2026, and $36.3 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 16.16 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 100.86 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 32.04 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 1.53 Bn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 1.40 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 607.80 Mn |
| 10 | BeyondSpring | 31.51 Mn | 31.51 Mn | - | 36.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.44 Mn |
| Mar 31, 2026 | 36.39 Mn |
| Dec 31, 2025 | 36.35 Mn |
| Sep 30, 2025 | 36.40 Mn |
| Jun 30, 2025 | 36.86 Mn |
| Mar 31, 2025 | 37.11 Mn |
| Dec 31, 2024 | 37.59 Mn |
| Jun 30, 2024 | 38.99 Mn |
| Dec 31, 2023 | 40.31 Mn |
| Jun 30, 2023 | 40.74 Mn |
| Dec 31, 2022 | 41.88 Mn |
| Jun 30, 2022 | 40.92 Mn |
| Dec 31, 2021 | 40.12 Mn |
| Sep 30, 2021 | 40.65 Mn |
| Jun 30, 2021 | 8.17 Mn |
| Mar 31, 2021 | 8.90 Mn |
| Dec 31, 2020 | 11.45 Mn |
| Sep 30, 2020 | 3.65 Mn |
| Jun 30, 2020 | 3.80 Mn |
| Mar 31, 2020 | 3.31 Mn |